Breaking News
January 17, 2019 - Pre-injury exercise reduces damage to both muscles and nerves, study finds
January 17, 2019 - Minimizing Antibody Size to Maximize Research Potential
January 17, 2019 - Research finds large genome in tiny forest defoliator
January 17, 2019 - Technology helps reduce the yearning for unhealthy food
January 17, 2019 - New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
January 17, 2019 - What you should know about teeth whitening
January 17, 2019 - Why Older Adults Should Eat More Protein (And Not Overdo Protein Shakes)
January 17, 2019 - Colorectal cancer mortality rates predicted to increase globally
January 17, 2019 - Scientists discover mutational signatures of tumor hypoxia
January 17, 2019 - New evidence shows how fever alters immune cells
January 17, 2019 - Researchers find new class of blood pressure-regulating peptides in vampire bat venom
January 17, 2019 - Promega to exhibit new Maxwell RSC48 platform at 2019 Festival of Genomics
January 17, 2019 - Study pinpoints immune cells that could be key to tackling hypertension
January 17, 2019 - Couples Intervention May Aid Partners of Diabetes Patients
January 17, 2019 - Your weight history may predict your heart failure risk
January 17, 2019 - Explore a cornucopia of accomplishments in prematurity research
January 17, 2019 - New study identifies four characteristics that predict severity of postpartum depression
January 17, 2019 - New, scalpel-free treatment for reducing Parkinson’s tremor gets FDA approval
January 17, 2019 - Neurobiologists uncover key component of how the human brain marks time
January 17, 2019 - LifeTime receives fund to develop a plan to embed its vision for healthier future
January 17, 2019 - WTC first responders at higher risk for head and neck cancers, study finds
January 17, 2019 - New NSF funded study may help physicians decrease brain injury deaths
January 17, 2019 - Ham bones contain peptides that could have cardioprotective effects
January 17, 2019 - Research finds how Candida albicans adapt to low oxygen levels to cause infection
January 17, 2019 - Cobra Biologics announces appointment of Dr Darrell Sleep as Director of Innovation
January 17, 2019 - Cellular protein that interacts with viruses appears to enable infection process of Zika virus
January 17, 2019 - Opioids Now More Deadly for Americans Than Traffic Accidents
January 17, 2019 - Women who start periods early are at greater risk of cardiovascular problems
January 17, 2019 - The brain-circuitry clash that keeps you from diving into that plate of ribs when you’re dining with royalty
January 17, 2019 - Poo transplant can successfully treat patients with ulcerative colitis
January 17, 2019 - Study suggests key role for glial cells in Parkinson’s disease
January 17, 2019 - Educational videos in clinical settings increase HPV vaccination rates among adolescents
January 17, 2019 - Better understanding of aggressive brain tumour
January 17, 2019 - Why is life expectancy in the U.S. going down? A Q&A
January 17, 2019 - The Electronics Industry Sees Money In Your Health
January 17, 2019 - Hypertension drug may improve effectiveness of ovarian cancer treatment
January 17, 2019 - Scientists reveal key mechanism in worms that controls cell’s response to stress
January 17, 2019 - How Patch Clamp Technology Can Benefit Ion Channel Research
January 16, 2019 - Researchers cultivate organoids that perfectly mimic blood vessels
January 16, 2019 - Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis
January 16, 2019 - Unraveling the genetic causes of skin cancer
January 16, 2019 - Higher percentages of saturated fat in low-carb diets may not harm cholesterol levels, new analysis suggests
January 16, 2019 - Using bottled or tap water impacts health benefits of green tea
January 16, 2019 - Best trained alert dogs have potential to improve Type 1 diabetes patients’ quality of life
January 16, 2019 - States with lower incidence of melanoma have higher mortality rates
January 16, 2019 - Pollution on the London Underground found to be dangerously high
January 16, 2019 - Breast cancer cells in mice coaxed to turn into harmless fat cells
January 16, 2019 - Study connects the genetic background of autistic spectrum disorders with stem cell dysfunction
January 16, 2019 - When activated, ‘social’ brain circuits inhibit feeding behavior in mice | News Center
January 16, 2019 - How Exercise May Help Keep Our Memory Sharp
January 16, 2019 - Researchers identify a key regulator that stops excessive inflammation
January 16, 2019 - TGF-beta signaling pathway in uterine cells protects against cancer
January 16, 2019 - MD Anderson Cancer Center collaborates with Dragonfly for new immunotherapy drug clinical trials
January 16, 2019 - Drug Repurposing May Provide More Psychiatric Tx Options
January 16, 2019 - A new brain imaging study challenges the dominant theoretical model of autism spectrum disorders
January 16, 2019 - GoFundMe CEO: ‘Gigantic Gaps’ In Health System Showing Up In Crowdfunding
January 16, 2019 - Induced neuronal cells derived from fibroblasts are similar to neurons in the brain
January 16, 2019 - New study finds link between childhood abuse and suicide in later life
January 16, 2019 - Lifestyle and health factors that are good for the heart can also prevent diabetes
January 16, 2019 - Scientists take another step in understanding bacteria that cause Salmonella epidemic
January 16, 2019 - Look to Your Aunts, Uncles and Parents for Clues to Your Longevity
January 16, 2019 - Study finds ADHD drugs are unlikely to cause cardiac damage in children who take them
January 16, 2019 - Call The Midwife! (If The Doctor Doesn’t Object)
January 16, 2019 - Changes in hippocampal structural connectivity differentiate responders of electroconvulsive therapy
January 16, 2019 - Study sheds light on the deadly venom of Mojave rattlesnakes
January 16, 2019 - University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure
January 16, 2019 - Sugar-based stent makes precarious sewing process easier
January 16, 2019 - FDA-approved drug hampers cancer metastasis in animal model, shows study
January 16, 2019 - Memories of past meals influence future food intake in rats
January 16, 2019 - Low-level cannabis use can change the adolescent brain
January 16, 2019 - MTC in Rouen acquires Robocath’s R-One robot for future healthcare practitioner training
January 16, 2019 - OSSIO granted FDA 510(k) market clearance for OSSIOfiber Bone Pin Family
January 16, 2019 - Childhood body composition may play a role in future respiratory health
January 16, 2019 - Outdated commissioning methods are failing mental health services in the UK, reveals report
January 16, 2019 - Unconventional immune cells trigger disturbed cytokine production in human spondyloarthritis
January 16, 2019 - Patients Turn To GoFundMe When Money And Hope Run Out
January 16, 2019 - Researchers develop novel viral identification method
January 16, 2019 - Study proposes improvements in pharmacological study of cognitive function enhancers in schizophrenia
January 16, 2019 - Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis
January 16, 2019 - Differences in geographic origin of genes may affect mitochondrial function
Apalutamide Slows Metastasis in Prostate Cancer

Apalutamide Slows Metastasis in Prostate Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and will be presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — Men with non-metastatic castration-resistant prostate cancer (nmCRPC) had a 2-year delay in the time to metastatic progression when treated with the new-generation androgen-receptor inhibitor apalutamide, a large randomized trial showed.

Patients randomized to apalutamide had a median metastasis-free survival (MFS) of 40.5 months versus 16.2 months for placebo treatment. The difference represented a 72% reduction in the hazard for metastatic progression or death, according to Eric Small, MD, of the University of California San Francisco, and colleagues.

Time to metastasis (TTM), progression-free survival (PFS), symptomatic progression, and PFS after subsequent therapy (PFS2) all favored apalutamide, Small reported at a press briefing prior to the Genitourinary Cancers Symposium (GUCS).

“Apalutamide was associated with a reduced risk of death, but that was not significant at this early interim analysis and will continue to be followed. The trend was certainly encouraging,” he said. “Treatment with apalutamide was generally well tolerated with no impact on quality-of-life [QoL] scores and with low rates of discontinuation due to treatment-related adverse events. Overall, these data suggest that apalutamide should be considered as a new standard of care for men with nonmetastatic castration-resistant prostate cancer.”

The results were consistent with those of the randomized PROSPER trial with enzalutamide (Xtandi), which also will be reported at GUCS, said press briefing moderator Sumanta Pal, MD, of City of Hope in Duarte, California. The abstract for the PROSPER trial showed a median MFS of 37 months for men treated enzalutamide (Xtandi) versus 15 months with placebo. Patients in both groups continued existing androgen deprivation therapy (ADT) after randomization.

“Until the results of studies presented at this meeting, there’s really been no obvious standard of care for these patients,” said Pal.

Noting that enzalutamide already has approval for more advanced prostate cancer, Pal added, “The familiarity that oncologists already have with enzalutamide may help with clinical adoption.”

However, the patient population targeted by the SPARTAN and PROSPER studies could be shrinking, Pal continued. SPARTAN investigators used conventional imaging modalities (CT and technetium bone scan) to assess patients’ status at enrollment and during the trial. Some newer forms of PET imaging may improve the ability to detect disease spread earlier, leading to early changes in clinical management, he said.

Metastatic CRPC remains uniformly fatal, associated with a median survival of about 2.5 years, Small noted. The condition arises in two way: metastatic hormone-sensitive prostate cancer and nmCRPC. Both conditions afford opportunities for interventions that delay or prevent progression to mCRPC, although as Pal noted, nmCRPC currently has no standard of care.

The primary objective of the SPARTAN trial was to determine whether treatment with apalutamide could delay development of metastases and the transition from nonmetastatic to metastatic CRPC. Apalutamide has a three-fold mechanism of action that could help accomplish the objective:

  • Prevention of androgen binding to receptor
  • Prevention of androgen receptor translocation to the nucleus
  • Blocking androgen receptor-mediated DNA transcription

Investigators at 332 centers worldwide enrolled 1,207 patients who had a baseline PSA doubling time of less than 5 month. The patients were randomized 2:1 to daily apalutamide or placebo, in addition to continuous ADT. The primary endpoint was MFS. Treatment continued until disease progression, and then patients had the option to switch to abiraterone (Zytiga) plus prednisone.

The trial ended prematurely after a planned interim analysis showed the trial had met the primary endpoint. The results showed that treatment with apalutamide was associated with a significant reduction in the hazard for MFS (95% CI 0.23-0.35, P<0.001). Small did not report results for secondary endpoints (TTM, PFS, and symptomatic progression) but said all were significantly improved in the apalutamide group versus the placebo group.

After a median follow-up of 20.3 months, the survival data remained immature to determine whether apalutamide treatment would lead to improved survival, said Small. However, the interim analysis showed a favorable trend in favor of apalutamide (P=0.07).

Apalutamide was generally well tolerated, as adverse events rates were similar in the two groups. Rates of discontinuation because of adverse events were 10.7% in the apalutamide group and 6.3% in the placebo group. Baseline health-related QoL scores were similar in the two groups and maintained throughout the study.

The study was supported by Janssen.

Small disclosed relevant relationships with Fortis, Gilead Sciences, Valeant Pharmaceuticals, Harpoon Therapeutics, and Janssen-Cilag.

2018-02-05T17:00:00-0500

Tagged with:

About author

Related Articles